ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Allarity Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.87−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $13.89M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.5670 (−39.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Allarity Therapeutics, Inc. reported revenue of $320.00K for fiscal 2025. Free cash flow was -$14.83M.
Revenue
$320.00K
FY2025
Operating income
-$10.80M
TTM Q2 2026
Free cash flow
-$14.83M
FY2025
EPS, diluted
-$0.78
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $13.89M
- P/E ratio
- –
- Price to sales
- 43.41
- Price to book
- 3.93
- Dividend yield
- –
- Free cash flow yield
- -106.75%
Fundamentals
- Revenue
- $320.00K
- Net income
- -$12.33M
- EPS, diluted
- -$0.78
- Free cash flow
- -$14.83M
- Book value per share
- $0.22
- Diluted shares
- 16M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$10.80M
Net income
-$12.33M
EPS, diluted
-$0.78
Free cash flow
–
Reported periodTrailing twelve months